Skip to main content
Erschienen in: Cardiovascular Drugs and Therapy 3/2011

01.06.2011 | Original Article

Reduced Thrombin Generation and Soluble P-selectin After Intravenous Enoxaparin During PCI

verfasst von: J. Kvasnička, J. Horák, Z. Zenáhlíková, Tomáš Kvasnička, S. Šimek, T. Kovárník, I. Malíková, A. Linhart, M. Aschermann

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The objective of our study was to identify changes in the coagulation and serum concentration of soluble P-selectin (sP-sel) after i.v. bolus of 0.75 mg/kg enoxaparin in a group of 33 patients during PCI.

Methods and results

As compared to baseline, i.v. enoxaparin increased anti -Xa activity and FIIa inhibition together with APTT and thrombin time tests within 20 min, that persisted for 60 min. At 6 h, the results of all tests had returned to baseline. In contrast, the level of prothrombin fragments (F1 + 2) decreased persistingly for a period of 6 h (baseline 1.19 ± 0.42 nmol/l, after 20 min 1.03 ± 0.46 nmol/l, after 60 min 1.06 ± 0.43 nmol/l, after 6 h 0.95 ± 0.40 nmol/l, p < 0.001 vs. baseline for all values). In addition, i.v. enoxaparin decreased serum sP-sel level (baseline 111.80 ± 37.05 ng/ml, after 20 min 87.80 ± 33.17 ng/ml, after 60 min 86.45 ± 29.15 ng/ml, after 6 h 92.24 ± 31.34 ng/ml, p < 0.001 vs. baseline value for all). sP-sel level mildly correlated with both F Xa inhibition (r = −0.275, p < 0.05) and F1 + 2 level (r = 0.274, p < 0.05).

Conclusion

Intravenous enoxaparin induced target F Xa inhibition (>0.6 IU/ml) for 60 min in 82% of study patients. During the 6 h of monitoring, a decrease of thrombin generation (F1 + 2) and sP-selectin levels were observed.
Literatur
1.
Zurück zum Zitat Borries M, Heins M, Fischer Y, Stiegler H, Peters A, Reinauer H, et al. Changes of hemostasis, endogenous fibrinolysis, platelet activation and endothelins after percutaneous transluminal coronary angioplasty in patiens with stable angina. J Am Coll Cardiol. 1999;34:486–93.PubMedCrossRef Borries M, Heins M, Fischer Y, Stiegler H, Peters A, Reinauer H, et al. Changes of hemostasis, endogenous fibrinolysis, platelet activation and endothelins after percutaneous transluminal coronary angioplasty in patiens with stable angina. J Am Coll Cardiol. 1999;34:486–93.PubMedCrossRef
2.
Zurück zum Zitat Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, et al. Task force for percutaneous coronary interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. Eur Heart J. 2005;26:804–47.PubMedCrossRef Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, et al. Task force for percutaneous coronary interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. Eur Heart J. 2005;26:804–47.PubMedCrossRef
3.
Zurück zum Zitat Montalescot G, Bal-dit-Sollier C, Chibedi D, Collet JP, Soulat T, Dalby M, et al. Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). Am J Cardiol. 2003;91:925–30.PubMedCrossRef Montalescot G, Bal-dit-Sollier C, Chibedi D, Collet JP, Soulat T, Dalby M, et al. Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). Am J Cardiol. 2003;91:925–30.PubMedCrossRef
4.
Zurück zum Zitat Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PEG, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. New Engl J Med. 2006;355:1006–17.PubMedCrossRef Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PEG, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. New Engl J Med. 2006;355:1006–17.PubMedCrossRef
5.
Zurück zum Zitat White HD. The ATOLL trial of enoxaparin in primary percutaneous coronary intervention. Eur Heart J. 2010;31:2826–7.PubMed White HD. The ATOLL trial of enoxaparin in primary percutaneous coronary intervention. Eur Heart J. 2010;31:2826–7.PubMed
6.
Zurück zum Zitat Tuttolomondo A, Di Raimondo D, Pecoraro R, Serio A, D’Aguanno G, Pinto A, et al. Immune-inflammatory markers and arterial stiffness indexes in subjects with Acute ischemic stroke. Atherosclerosis. 2010;213:311–8.PubMedCrossRef Tuttolomondo A, Di Raimondo D, Pecoraro R, Serio A, D’Aguanno G, Pinto A, et al. Immune-inflammatory markers and arterial stiffness indexes in subjects with Acute ischemic stroke. Atherosclerosis. 2010;213:311–8.PubMedCrossRef
7.
Zurück zum Zitat Serrano Jr CV, Nicolau JC, Venturinelli M, Baracioli LM, Anders RJ, Cannon CP, et al. Role of oral blockade of platelet glycoprotein IIb/IIIa on neutrophil activation in patients with acute coronary syndromes. Cardiovasc Drugs Ther. 2003;17:129–32.PubMedCrossRef Serrano Jr CV, Nicolau JC, Venturinelli M, Baracioli LM, Anders RJ, Cannon CP, et al. Role of oral blockade of platelet glycoprotein IIb/IIIa on neutrophil activation in patients with acute coronary syndromes. Cardiovasc Drugs Ther. 2003;17:129–32.PubMedCrossRef
8.
Zurück zum Zitat Hillis GS, Terregino C, Taggart P, Killian A, Zhao N, Dalsey WC, et al. Elevated soluble P-selectin levels are associated with an increased risk of early adverse events in patients with presumed myocardial ischemia. Am Heart J. 2002;143:235–41.PubMedCrossRef Hillis GS, Terregino C, Taggart P, Killian A, Zhao N, Dalsey WC, et al. Elevated soluble P-selectin levels are associated with an increased risk of early adverse events in patients with presumed myocardial ischemia. Am Heart J. 2002;143:235–41.PubMedCrossRef
9.
Zurück zum Zitat Pernerstorfer T, Eichler HG, Stohlawetz P, Speiser W, Jilma B. Effects of heparin and aspirin on circulating P-selectin, E-selectin and von Willebrand factor levels in healthy men. Atherosclerosis. 2001;155:389–93.PubMedCrossRef Pernerstorfer T, Eichler HG, Stohlawetz P, Speiser W, Jilma B. Effects of heparin and aspirin on circulating P-selectin, E-selectin and von Willebrand factor levels in healthy men. Atherosclerosis. 2001;155:389–93.PubMedCrossRef
10.
Zurück zum Zitat Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al. Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2010;31:2501–55.PubMedCrossRef Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al. Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2010;31:2501–55.PubMedCrossRef
11.
Zurück zum Zitat Thom J, Gilmore G, Yi Q, Hankey GJ, Eikelboom JW. Measurement of soluble P-selectin and soluble CD40 ligand in serum and plasma. J Thromb Haemost. 2004;2:2067–9.PubMedCrossRef Thom J, Gilmore G, Yi Q, Hankey GJ, Eikelboom JW. Measurement of soluble P-selectin and soluble CD40 ligand in serum and plasma. J Thromb Haemost. 2004;2:2067–9.PubMedCrossRef
12.
Zurück zum Zitat Bland JM, Altman DG. Calculating correlation coefficients with repeated observations: Part 1—correlation within subjects. BMJ. 1995;310:446.PubMed Bland JM, Altman DG. Calculating correlation coefficients with repeated observations: Part 1—correlation within subjects. BMJ. 1995;310:446.PubMed
13.
Zurück zum Zitat Kereiakes DJ, Tcheng J, Fry ET, Bhatt DL, Bosker G, Diez JG, et al. The CATH (Cardiac Cathetrization and Antithrombotic Therapy and Tools in the Hospital) Clinical Consensus® Panel Report : Acute Coronary Syndromes. Site-, speciality-, and spectrum-of-care strategies for optimizing patient outcomes in NSTE-ACS and ST-elevation myocardial infarction (STEMI). Interventional Cardiology Consensus Reports™, American Health Consultants, Atlanta, USA: Thomson; 2003. p. 1–36. Kereiakes DJ, Tcheng J, Fry ET, Bhatt DL, Bosker G, Diez JG, et al. The CATH (Cardiac Cathetrization and Antithrombotic Therapy and Tools in the Hospital) Clinical Consensus® Panel Report : Acute Coronary Syndromes. Site-, speciality-, and spectrum-of-care strategies for optimizing patient outcomes in NSTE-ACS and ST-elevation myocardial infarction (STEMI). Interventional Cardiology Consensus Reports™, American Health Consultants, Atlanta, USA: Thomson; 2003. p. 1–36.
14.
Zurück zum Zitat Martin JL, Fry ET, Sanderink GJ, Atherley TH, Guimart CM, Chevalier PJ, et al. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: the Pharmacokinetics of Enoxaparin in PCI (PEPCI) Study. Catheter Cardiovasc Interv. 2004;61:163–70.PubMedCrossRef Martin JL, Fry ET, Sanderink GJ, Atherley TH, Guimart CM, Chevalier PJ, et al. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: the Pharmacokinetics of Enoxaparin in PCI (PEPCI) Study. Catheter Cardiovasc Interv. 2004;61:163–70.PubMedCrossRef
15.
Zurück zum Zitat Manoukian SV. Predictors and impact of bleeding complications in percutaneous Coronary intervention, acute coronary syndromes, and ST-segment elevation Myocardial infarction. Am J Cardiol. 2009;104:9C–15C.PubMedCrossRef Manoukian SV. Predictors and impact of bleeding complications in percutaneous Coronary intervention, acute coronary syndromes, and ST-segment elevation Myocardial infarction. Am J Cardiol. 2009;104:9C–15C.PubMedCrossRef
16.
Zurück zum Zitat Kereiakes DJ, Grines C, Fry E, Esente P, Hoppensteadt D, Midei M, et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol. 2001;13:272–8.PubMed Kereiakes DJ, Grines C, Fry E, Esente P, Hoppensteadt D, Midei M, et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol. 2001;13:272–8.PubMed
17.
Zurück zum Zitat Sanchez-Pena P, Hulot JS, Urien S, Ankri A, Collet JP, Choussat R, et al. Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model. Br J Clin Pharmacol. 2005;60:364–73.PubMedCrossRef Sanchez-Pena P, Hulot JS, Urien S, Ankri A, Collet JP, Choussat R, et al. Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model. Br J Clin Pharmacol. 2005;60:364–73.PubMedCrossRef
18.
Zurück zum Zitat Ambrose JA, Hawkey M, Badimon JJ, Coppola J, Geagea J, Rentrop KP, et al. In vivo demonstration of an antithrombin effect of abciximab. Am J Cardiol. 2000;86:150–2.PubMedCrossRef Ambrose JA, Hawkey M, Badimon JJ, Coppola J, Geagea J, Rentrop KP, et al. In vivo demonstration of an antithrombin effect of abciximab. Am J Cardiol. 2000;86:150–2.PubMedCrossRef
19.
Zurück zum Zitat Kereiakes DJ, Tcheng J, Fry ET, Bhatt DL, Bosker G, Diez JG, et al. Pharmacoinvasive management of acute coronary syndrome in the setting of percutaneous coronary intervention: evidence-based, site-and spectrum-of-care strategies for optimizing patients outcomes in NSTE-ACS. J Invasive Cardiol. 2003;15:536–53.PubMed Kereiakes DJ, Tcheng J, Fry ET, Bhatt DL, Bosker G, Diez JG, et al. Pharmacoinvasive management of acute coronary syndrome in the setting of percutaneous coronary intervention: evidence-based, site-and spectrum-of-care strategies for optimizing patients outcomes in NSTE-ACS. J Invasive Cardiol. 2003;15:536–53.PubMed
20.
Zurück zum Zitat Aslam MS, Sundberg S, Sabri MN, Cooke D, Lakier JB. Pharmacokinetics of intravenous/subcutaneous enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2002;57:187–90.PubMedCrossRef Aslam MS, Sundberg S, Sabri MN, Cooke D, Lakier JB. Pharmacokinetics of intravenous/subcutaneous enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2002;57:187–90.PubMedCrossRef
21.
Zurück zum Zitat Greaves M, Presto FE. Approach to the bleeding patients. In: Colman RW, Hirsh J, Marder V, editors. Hemostasis and thrombosis. Basic principles and clinical practice. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 784–813. Greaves M, Presto FE. Approach to the bleeding patients. In: Colman RW, Hirsh J, Marder V, editors. Hemostasis and thrombosis. Basic principles and clinical practice. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 784–813.
22.
Zurück zum Zitat Samama MM, Desnoyers P, Gerotziafas GT. Low molecular weight heparins: a comparative review of pharmacodynamics, clinical pharmacology. In: Lugassy G, Brenner B, Schulman S, Samama MM, Cohen M, editors. Thrombosis and antithrombotic therapy. London: Martin Dunitz Ltd; 2000. p. 71–96. Samama MM, Desnoyers P, Gerotziafas GT. Low molecular weight heparins: a comparative review of pharmacodynamics, clinical pharmacology. In: Lugassy G, Brenner B, Schulman S, Samama MM, Cohen M, editors. Thrombosis and antithrombotic therapy. London: Martin Dunitz Ltd; 2000. p. 71–96.
23.
Zurück zum Zitat Bara L, Billaud E, Gramond G, Kher A, Samama M. Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res. 1985;39:631–6.PubMedCrossRef Bara L, Billaud E, Gramond G, Kher A, Samama M. Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res. 1985;39:631–6.PubMedCrossRef
24.
Zurück zum Zitat Dawes J, Bara L, Billaud E, Samama M. Relationship between biological activity and concentration of a low-molecular-weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Haemostasis. 1986;16:116–22.PubMed Dawes J, Bara L, Billaud E, Samama M. Relationship between biological activity and concentration of a low-molecular-weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Haemostasis. 1986;16:116–22.PubMed
25.
Zurück zum Zitat Dumaine R, Borentain M, Bertel O, Bode C, Gallo R, White HD, et al. Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials. Arch Intern Med. 2007;167:2423–30.PubMedCrossRef Dumaine R, Borentain M, Bertel O, Bode C, Gallo R, White HD, et al. Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials. Arch Intern Med. 2007;167:2423–30.PubMedCrossRef
26.
Zurück zum Zitat Granger CB, Miller J, Bovill E, Gruber A, Tracy R, Krucoff M, et al. Rebound increase in trombin generation and activity after cessation of intravenous heparin in patiens with acute coronary syndromes. Circulation. 1995;91:1929–35.PubMed Granger CB, Miller J, Bovill E, Gruber A, Tracy R, Krucoff M, et al. Rebound increase in trombin generation and activity after cessation of intravenous heparin in patiens with acute coronary syndromes. Circulation. 1995;91:1929–35.PubMed
27.
Zurück zum Zitat Doi N, Nishio K, Nakatani H, Hayashi T, Miyamoto S, Hashimoto T, et al. Decreased plasma soluble P-selectin level in coronary sinus after successful coronary angioplasty in patients with unstable angina. J Cardiol. 1999;33:251–6.PubMed Doi N, Nishio K, Nakatani H, Hayashi T, Miyamoto S, Hashimoto T, et al. Decreased plasma soluble P-selectin level in coronary sinus after successful coronary angioplasty in patients with unstable angina. J Cardiol. 1999;33:251–6.PubMed
28.
Zurück zum Zitat Berger G, Hartwell DW, Wagner DD. P-selectin and platelet clearance. Blood. 1998;92:4446–52.PubMed Berger G, Hartwell DW, Wagner DD. P-selectin and platelet clearance. Blood. 1998;92:4446–52.PubMed
29.
Zurück zum Zitat Cleator JH, Zhu WQ, Vaughan DE, Hamm HE. Differential regulation of endothelial exocytosis of P-selectin and von Willebrand factor by protease-activated receptors and cAMP. Blood. 2006;107:2736–44.PubMedCrossRef Cleator JH, Zhu WQ, Vaughan DE, Hamm HE. Differential regulation of endothelial exocytosis of P-selectin and von Willebrand factor by protease-activated receptors and cAMP. Blood. 2006;107:2736–44.PubMedCrossRef
30.
Zurück zum Zitat Ishiwata N, Takio K, Katayama M, Watanabe K, Titani K, Ikeda Y, et al. Alternatively spliced isoform of P-selectin is present in vivo as a soluble molecule. J Biol Chem. 1994;38:23708–15. Ishiwata N, Takio K, Katayama M, Watanabe K, Titani K, Ikeda Y, et al. Alternatively spliced isoform of P-selectin is present in vivo as a soluble molecule. J Biol Chem. 1994;38:23708–15.
31.
Zurück zum Zitat Libersan D, Khalil A, Dagenais P, Quan E, Delorme F, Uzan A, et al. The molecular weight heparin, enoxaparin, limits infarct size at reperfusion in the dog. Cardiovasc Res. 1998;37:656–66.PubMedCrossRef Libersan D, Khalil A, Dagenais P, Quan E, Delorme F, Uzan A, et al. The molecular weight heparin, enoxaparin, limits infarct size at reperfusion in the dog. Cardiovasc Res. 1998;37:656–66.PubMedCrossRef
32.
Zurück zum Zitat Klinkhardt U, Bauersachs R, Adams J, Graff J, Lindhoff-Last E, Harder S. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther. 2003;73:232–41.PubMedCrossRef Klinkhardt U, Bauersachs R, Adams J, Graff J, Lindhoff-Last E, Harder S. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther. 2003;73:232–41.PubMedCrossRef
Metadaten
Titel
Reduced Thrombin Generation and Soluble P-selectin After Intravenous Enoxaparin During PCI
verfasst von
J. Kvasnička
J. Horák
Z. Zenáhlíková
Tomáš Kvasnička
S. Šimek
T. Kovárník
I. Malíková
A. Linhart
M. Aschermann
Publikationsdatum
01.06.2011
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 3/2011
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-011-6301-0

Weitere Artikel der Ausgabe 3/2011

Cardiovascular Drugs and Therapy 3/2011 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.